化疗对食道和胃食道结合腺癌的脂肪组织中的线粒体功能的影响,有或没有相关的缓解症:前性比较观察研究 (ChiFMeOE) 的协议
Ophélie Bacoeur-Ouzillou1,2, Lisa Guerrier2, Julianne Touron3,4
1Digestive and Hepatobiliary Surgery department, CHU Clermont-Ferrand, Clermont-Ferrand, France obacoeurouzillou1@chu-clermontferrand.fr.
BMJ open
|October 24, 2024
概括
癌症缓解症增加脂肪组织的线粒体代谢. 化疗可以减轻这种影响,促使ChiFMeOE研究在食道癌症患者中调查脂肪细胞因子.
科学领域:
- 在瘤学瘤学.
- 代谢研究 研究 代谢研究
- 线粒体生物学 线粒体生物学
背景情况:
- ,一种代谢并发症,在消化系统癌症 (如食道癌) 中很常见.
- 脂肪组织中的线粒体在癌症缓冲症病理生理学中发挥作用.
- 化疗可能会影响脂肪组织中的线粒体功能.
研究的目的:
- 为了确定脂肪细胞因素,有助于能量失衡的癌症缓解症.
- 为了确定这些因素对食道胃癌患者化疗的反应.
主要方法:
- 单中心观察性研究 (ChiFMeOE),包括60名食道和胃食道结腺癌患者.
- 在新辅助化疗前后收集内脏和皮下脂肪组织活检.
- 评估线粒体呼吸速率 (主要结果),酶活性,蛋白质/基因表达,瘤特征和营养状况.
主要成果:
- 该部分应在研究完成并获得结果后填写.
结论:
- 该部分应在研究完成并获得结果后填写.
相关概念视频
Electron Transport Chain: Complex I and II
12.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.0K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
175
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
175


